Company intelligence / Profile preview

Nuvonis Technologies

Vienna, Vienna, Austrianuvonis.com ↗

Ownership: Private
Development stage: Other

Overview

Nuvonis Technologies provides fully characterized, animal component-free GMP Vero cell banks and proprietary avian cell lines for use in viral vaccine and vector manufacturing. Their platforms are designed to reduce development timelines, improve quality, and minimize risks in product development. The company also offers technical support for process development, virus purification methods, influenza strain optimization, and reverse genetics. Their products are used by both small biotech firms and major pharmaceutical companies.

Therapeutic areas: OtherInfectious Diseases
Modalities: Cell substrate (Vero cells, avian cell lines)Biologic (for vaccine and vector production)
Industry: Chemicals & Materials

Partnerships

Charles River Laboratories (GMP storage partner in the USA)

Beyond the preview

Go deeper on Nuvonis Technologies.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Nuvonis Technologies.

Explore the full profile